Meeting Minutes

Institution:	Ophthalmic Consultants of Boston
Meeting Date:	April 15, 2026
Meeting Time	12:00 PM Eastern Time
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public

Members in Attendance:

Member	Voting	Member Type
Bavaret, Tammy	Yes	Chair: Biosafety Expert/HGT Expert
Rastein, Daniel	Yes	Core Member: Biosafety Expert/HGT Expert
Campbell, Mark	Yes	Core Member: Biosafety Expert/HGT Expert
Schlimgen, Ryan	Yes	Local Unaffiliated Member
Nowak, Alison	No	Site Contact

Invited Members Not in Attendance:

Member	Voting	Member Type
Sanchez-Cano, Carolina	Yes	Local Unaffiliated Member

Guests:	None
Staff:	Hemmelgarn, Marian

Call to Order: The IBC Chair called the meeting to order at 12:04 PM. A quorum was present as defined in the Sabai IBC Charter.

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

Public Comments: No public comments were made prior to or at the meeting.

Review of Prior Business: None

Previous Meeting Minutes: Minutes from 5/14/25 were approved by the IBC with no changes. There were no votes against and no abstentions.

New Business:

PI:	Heier, Jeffrey MD
Sponsor:	Perceive Biotherapeutics, Inc.
Protocol:	PBI-AMD-002 A Phase 1/2a Study of VOY-101 in Subjects with Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Review Type:	Annual Review
NIH Guidelines Section:	III-C-1

Trial Summary: PBI-AMD-002 is an open-label, multi-center, two-part Phase I/IIa clinical trial sponsored by Perceive Biotherapeutics, Inc. and designed to assess the safety, tolerability, and efficacy of a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA) secondary to advanced non-neovascular age-related macular degeneration (AMD). VOY-101 is a recombinant adeno-associated viral vector, AAV serotype 2, containing a transgene that encodes the truncated isoform of human Complement Factor H (hCFHT). The investigational product (IP) is administered by IVT injection.

Biosafety Containment Level (BSL): The study agent VOY-101 is based on a replication-defective, recombinant Risk Group 1 AAV with no known oncogene or toxin and manufactured in the absence of helper virus, thus BSL-1 is considered the recommended containment level under the NIH Guidelines. The administration of this agent in a clinical setting further requires compliance with the OSHA Bloodborne Pathogen Standard (29 CFR 1910.1030).

Risk Assessment and Discussion:

- The Committee reviewed the clinical trial Sponsor's study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
    - In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, and needlestick exposures of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
    - The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
    - The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
    - The Site confirmed that staff members receive Bloodborne Pathogens training.
    - Occupational Health Recommendations: None

- The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.

- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
  - The Site verified that the information provided by the Chair was accurate.
  - The Site confirmed the accuracy of the Annual Review Report.
  - In response to a question from the committee regarding the priming step for the agent, the Site indicated they will be priming the syringe into a sterile gauze or into a cup with disinfectant wipe. The Committee requested this additional detail be included in the Facility Details Form.

Motion: A motion of Full Approval for the study at BSL-1 plus Standard Precautions was passed by unanimous vote.

- Contingencies stated by the Committee: None

- Stipulations stated by the Committee: None

Review of Incidents: Nothing to report.

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 12:30 PM

Post-Meeting Pre-Approval Note: None